For decades, Parkinson’s disease has been framed as a simple story of dwindling dopamine, a slow erosion of the brain’s ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has announced a new clinical study titled ‘A ...

Explore dopamine's role in movement and how it challenges long-standing theories about motor control and Parkinson's disease ...

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials ...

IRLAB receives approval for phase Ib study with IRL757 in Parkinson’s disease: Gothenburg, Sweden Friday, December 26, 2025, 17:00 Hrs [IST] Sweden headquartered IRLAB, a compan ...

Van Andel Institute and Cure Parkinson's have renewed a funding agreement to support the International Linked Clinical Trials Program, the world's largest drug repurposing clinical trial initiative ...

Now, scientists at Queen Mary University of London have found something surprising. They discovered that some drugs used to ...

Van Andel Institute and Cure Parkinson’s have renewed a funding agreement to support the International Linked Clinical Trials Program, the world’s largest drug repurposing clinical trial initiative ...

In this Innovation Spotlight, Gene Mack, the chief executive officer of Gain Therapeutics, discusses the company’s Magellan™ platform, which uss machine learning and structural modeling to identify ...

Researchers have been chasing the causes of Parkinson’s disease for more than a century, yet its hallmark feature — microscopic protein clumps called Lewy bodies — remains enigmatic: Patients with ...

A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...